[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100192658":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":10,"locations":10,"responsibleParty":16,"collaborators":10,"id":18,"slug":19,"hasResults":20,"nctId":21,"briefTitle":22,"officialTitle":23,"acronym":10,"eligibilityCriteria":24,"healthyVolunteers":25,"sex":26,"minAge":27,"maxAge":28,"enrollmentInfo":29,"targetDuration":10,"studyType":32,"phases":10,"briefSummary":33,"conditions":34,"keywords":36,"overallStatus":38,"whyStopped":10,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":10},{"fullName":5,"class":6},"AbbVie","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Participants with high rheumatoid arthritis disease activity",null,"Participants who received adalimumab treatment",[13],{"name":14,"affiliation":5,"role":15},"Sarina Kurimoto, MD","STUDY_DIRECTOR",{"type":17,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100192658","assessment-of-the-safety-of-adalimumab-in-rheumatoid-arthritis-patients-showing-rapid-progression-of-structural-damage-of-the-joints-who-have-no-prior-history-of-treatment-with-disease-modifying-anti-rheumatic-drugs-or-biological-agents-100192658",true,"NCT01783730","Assessment of the Safety of Adalimumab in Rheumatoid Arthritis Patients Showing Rapid Progression of Structural Damage of the Joints, Who Have no Prior History of Treatment With Disease-modifying Anti-rheumatic Drugs or Biological Agents","Special Investigation in Japanese Rheumatoid Arthritis Patients Who Have no Previous Use of DMARDs and Biological Agents","Inclusion Criteria:\n\n1. High disease activity, with poor prognostic factors (e.g., rheumatoid factor \\[RF\\]-positive, anti-cyclic citrullinated peptide \\[CCP\\] antibody-positive, or bone erosion)\n2. Combination of adalimumab and methotrexate will be started\n3. No prior history of treatment with disease-modifying anti-rheumatic drugs\n4. No prior history of treatment with biological agents\n5. Adalimumab dosed according to the registered product label\n6. Signed informed consent\n\nExclusion Criteria:\n\nThere were no specific exclusion criteria.",false,"ALL","15 Years","99 Years",{"count":30,"type":31},163,"ACTUAL","OBSERVATIONAL","This study was conducted to examine the safety profile and the effectiveness in daily clinical practice of adalimumab in rheumatoid arthritis participants showing rapid progression of structural damage of the joints, who had no prior history of treatment with disease-modifying anti-rheumatic drugs or biological agents.",[35],"Rheumatoid Arthritis",[37],"Rheumatoid arthritis","COMPLETED","2016-09-02",{"date":41,"type":42},"2016-10-26","ESTIMATED",{"date":44,"type":10},"2013-02",{"date":46,"type":31},"2015-09",{"name":5,"class":6}]